Synergies: the number that justifies the premium
6 min read · updated July 2, 2026
Here's the question that hangs over every acquisition: why is the buyer paying more than the target is worth on its own?
The answer is almost always synergies, the extra value the combined company can create that neither side could alone. A buyer pays a control premium (typically 20% to 40% above the unaffected share price) and then has to earn that premium back. Synergies are how. If the buyer can't point to real synergies, it's just overpaying with a story attached.
The premium is the price. The synergies are the justification. A deal only makes sense if the present value of synergies is worth more than the premium you paid. Miss that and you've transferred wealth from your shareholders to theirs.
The two flavors, and why one is trusted more
There are two kinds of synergies, and interviewers care a lot that you know the difference in credibility.
Cost synergies are the savings from cutting duplicate stuff. Two head offices become one. Two finance teams, one. Overlapping factories, distribution centers, back-office systems, board seats: you don't need two of each. These are inside the buyer's control. You can put a name and a dollar figure on each cut before you sign. That's why they're credible and why they show up fast, usually within the first year or two.
Revenue synergies are the extra sales the combined company hopes to generate. Cross-sell the acquirer's product to the target's customers. Bundle. Enter a new region using the other side's sales force. The logic sounds great in a pitch. The problem is that revenue synergies depend on customers behaving the way you predict, and customers don't take orders from a deal model. They churn. They renegotiate. Sales cycles run long.
Trusting revenue synergies as much as cost synergies. They are not the same animal. Cost cuts are things you do to yourself; revenue synergies are things you hope other people (customers) do for you. Seasoned buyers and their boards heavily haircut revenue synergies, often to zero for deal-justification purposes, and treat them as upside rather than the reason to do the deal. If a banker leans on revenue synergies to make the math work, that's a red flag, not a green light.
How synergies flow into the numbers
Synergies land in the pro forma income statement. Cost synergies lift operating income directly (lower EBITDA costs). Revenue synergies add sales, and you flow them through at the incremental margin, not the full revenue line.
For valuation, you value the synergy stream the same way you'd value any cash flow: capitalize the after-tax annual benefit. Say you identify $50 of annual pretax cost synergies. At a 20% tax rate that's $40 after tax. Treat it as a perpetuity discounted at 10%:
That $400 is the ceiling on what those synergies are worth to you. It's also the number that has to cover your premium.
The premium math, walked through
Let's make it concrete. A target has a standalone equity value of $1,000. You pay a 30% premium, so $1,300. The premium you handed the seller is $300.
| Item | Value | | --- | --- | | Target standalone equity value | $1,000 | | Premium paid (30%) | $300 | | Price paid | $1,300 | | PV of synergies | $400 | | Net value created for the buyer | $100 |
You paid $300 of premium and captured $400 of synergy value. You keep the $100 difference. Good deal.
Now watch what happens if you get into a bidding war and pay a 40% premium, or $1,400:
You did all the work, took all the integration risk, and captured nothing. Every dollar of synergy value went to the seller in the price. And if synergies come in even 10% light, the deal is now value-destructive.
Synergies belong to the buyer's shareholders only to the extent you don't pay them away in the premium. The seller's negotiating goal is to extract as much of your synergy value as possible. Your goal is to keep it. The whole fight over price is really a fight over who gets the synergies.
Accretion is not the same as value creation
A quick but important warning. A deal can be accretive to EPS and still destroy value, and a deal can be dilutive in year one yet create real value. Cheap debt can make almost anything accretive on paper without a single synergy. Don't confuse the accretion/dilution question ("what happens to my EPS?") with the value question ("did I pay less than what this is worth to me?"). They answer different things. For the mechanics of the first one, see accretion and dilution. This article is about the second.
Where beginners go wrong on the exam
Three traps come up constantly:
Treating the synergy number as a given. Interviewers will push: how did you get to $50? Which costs? By when? If you can't decompose it, you don't own it.
Double-counting or ignoring the cost to achieve. Synergies aren't free. There are one-time restructuring, severance, and integration costs (often quoted as a multiple of the annual run-rate savings). Net them out.
Forgetting that the premium and the synergies are linked. The right way to frame any deal is: premium paid versus synergy value captured. If you want the bigger picture on how a purchase price gets financed and allocated, that connects to the combined entity and purchase accounting work you'd do next.
When you're asked "would you do this deal?", don't jump to EPS. Sequence it out loud: standalone value, then premium, then estimate synergy PV (and say out loud that you're haircutting revenue synergies and netting cost-to-achieve), then compare premium to synergy value. If synergies clear the premium with room to spare, yes. If they don't, no, and say why. That structured walk-through, delivered in under a minute without reaching for a calculator, is the depth that separates you in a Superday. Anyone can define a synergy. You're showing you know who the value belongs to.
Glossary
New to the lingo? Every term used above, in plain English.
- Synergies
- The extra value two companies expect to create by combining, usually cost savings or added revenue that neither could achieve alone.
- Equity Value
- The slice of a company that belongs to its shareholders. For a public company this is the market capitalization (share price times shares outstanding).
- EBITDA
- Earnings Before Interest, Taxes, Depreciation, and Amortization. A rough proxy for a company’s operating cash profit, before financing and accounting choices.
- EPS (Earnings Per Share)
- A company’s profit divided by its number of shares. It is the per-share slice of earnings that each shareholder owns.
- Accretion
- A deal is accretive when it raises the buyer’s earnings per share (EPS).
- Dilution
- A deal is dilutive when it lowers the buyer’s earnings per share (EPS).
Make it stick
Drill what you just learned
